**Problem Set 7 - Due Sunday October Time required ~ 85 min.**

**1.** (10 pts, 10 min) Chymotrypsin binds Phe as a substrate based on the nonpolar Met192 and Val213 in its specificity pocket. View the JMol structure of chymotrypsin with different substrates to determine what additional interactions stabilize Tyr and Trp as bound substrates.

**2.** (10 pts, 20 min). You work for a drug company and you are trying to determine which two drugs would be better to use in clinical trials to inhibit HIV reverse transcriptase. The structure of the normal substrate and the two drugs are shown to the right.

|  |  |  |  |
| --- | --- | --- | --- |
| [S] M | *V* (μM/sec)No drug | *V* (μM/sec)[A]=10μM | *V* (μM/sec)[B]=10μM |
| 0 | 0 | 0 | 0 |
| 0.5.x10-6 | 66 | 12 | 33 |
| 1.0 x 10-6 | 101 | 22 | 51 |
| 1.5 x 10-6 | 122 | 31 | 59 |
| 2.0 x 10-6 | 133 | 40 | 66 |
| 5.0 x 10-6 | 167 | 76 | 82 |
| 10.0 x 10-6 | 180 | 110 | 92 |

i) What is the role of this enzyme in the HIV lifecycle and indicate why it would be a particularly good drug target (2 pts).

ii) The table on the right gives the steady state velocities acquired with no inhibitor and with 10 uM of inhibitor A or 10 uM of inhibitor B.

Determine the appropriate inhibition constants (KI or KI and K'I) from the steady-state data using a double reciprocal plot. You should briefly discuss how you decided to determine KI versus KI and KI’, i.e. why a compound is a competitive or mixed type inhibitor. Note that there is some experimental error in the data, so the y-intercept on the double reciprocal plot for the competitive inhibitor may not be exactly the same as the value obtained in the absence of the inhibitor. Submit the double reciprocal plot with your problem set (5 pts).

iv) Can you determine from these data which inhibitor will make the best drug? If not, what additional information beyond the binding affinities will be required? Many factors come into play in making a successful drug besides how well it may bind to its target enzyme in a laboratory setting. Think about where drugs have to function and what might be unknown in that environment. [Hint: A plot of *v* versus [S] in the absence and the presence of each inhibitor may give you an idea.] (3 pts)

|  |  |  |
| --- | --- | --- |
| **Enzyme** | **Drug** | **KI** |
| Wild-type (WT) | Cyclohexane (Cyc) |  |
| Mutant | Cyclohexane |  |
| Mutant | Drug 1 (amide) |  |
| Mutant | Drug 2 (alcohol) |  |
| Mutant | Drug 3 (methyl) |  |

 **3.** (21 pts, 25 min) The Jmol page associated with this problem set shows wild-type and a mutant HIV protease in complex with a number of different HIV drugs. One of these drugs is the same as the one presented in class. This particular drug contains a cyclohexane ring at one end and it binds to the wild-type enzyme with high affinity. Three different drugs, with alteration in the cyclohexane ring, have been developed for the purpose of inactivating the *mutant* HIV protease (structures given at the end of question).

i) What feature of the HIV life-cycle leads to a high level of mutations in the HIV genetic material (2 pts)?

ii) Based on the Jmol page, which residue is altered in the mutant HIV protease? How has it been changed? (1 pt)

iii) Does this residue contribute mostly to catalysis or specificity? Justify your answer. (2 pts)

iv) Determine the KI values using solver. Download the spreadsheet for this problem set (do not use the one from recitation). It is all set up for you, except for column K (predicted values for WT-Cyc). You will have to generate the correct formula for those cells, using the following (KM = $W$1, VMAX = $W$2, alpha = $W$3). You have to adjust VMAX to get solver to fit the data; adjust the value of W2 to do so. Note that we have assumed the same VMAX and KM for the wild-type and the mutant. Include a graph that shows the best fit to all of the data. The concentration of the drug is 10 nM (5 pts).

v) Explain, with reference to the change in the KI values and the structure of the two enzymes, why the affinity to the original cyclohexane drug has been affected by this mutation (e.g. compare lines 1 and 2 in the above table as well as the interaction between the protein and the drug.) (3 pts)

vi) Which of the three drugs would be the *worst* inhibitor of the mutant protease? Justify your answer with reference to the KI values as well as the interaction between the drug and the mutant enzyme. Please include a simple sketch of the interaction between the drug and the inhibitor (4 pts).

vi) Which of the three drugs would be the *best* inhibitor of the mutant protease? Justify your answer with reference to the KI values as well as the interaction between the drug and the mutant enzyme. A simple sketch of the interaction between the drug and the enzyme would be useful (4 pts).

|  |  |
| --- | --- |
| **Name** | **Key** |
| Moza, Ayah A., Mohammed A. | D |
| Asma, Amna, Lulwa | H  |
| Alreem, Sara, Maryam | J  |
| Laila, Mahnoor, Maher | M  |
| Mohammad H, Syeda, Thamanna | Q  |
| Ayah S, Mohammed S | T  |

**4.** (20 pts, 30 min) You are given an equal mixture of all the proteins listed in the table below. The size of the protein, its solubility in ammonium sulfate, and the number of charged residues are presented in this table. Using the on-line protein purification simulator, develop a purification scheme that will result in the purification of one of the proteins in their native, non-denatured, form. The protein that you need to purify depends on your last name. Enter the value in the ‘Key” column on the first page of the simulator, where it asks for your “first letter last name:”. The correct target protein should be assigned to you.

In developing your purification scheme, you may use ammonium sulfate precipitation, size exclusion (gel filtration), anion exchange, and cation exchange chromatography.

After completing the purification of your protein, you must click on the submit button to send your work to the server. Feel free to make as many practice runs as you like, but only hit submit when you are satisfied with your purification scheme and want to submit it for grading.

**Starting amount and Yield:** The initial number of enzymatic units of each protein is 100, therefore your % yield = number of final units.

**How to evaluate purity?** The specific activity of each protein can be found on the “Handbook” tab and it is also listed below. Due to round off error, your final specific activity may be ~5% lower, this will be considered as a pure protein. The specific activities of the pure protein are also listed in the table.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Protein** | **Sol.****AmmSulf\*** | **# Residues** | **Number of Charged Residues** | **Spec. Act. (pure protein)** | **Key: Enter as “***first letter of last name***”** |
| **Acidic Asp+Glu** | **His** | **Lys** | **Arg** |
| Fatty Acid Binding Protein | 1.5 | 131 | 10 | 1 | 10 | 5 | 69.3 | Recitation |
| Myoglobin  | 3.5 | 153 | 10 | 10 | 15 | 5 | 59.4 | D |
| Hen Lysozyme | 5.0 | 130 | 5 | 1 | 5 | 15 | 69.9 | H |
| Quail Lysozyme | 6.0 | 129 | 5 | 5 | 5 | 15 | 70.4 | J |
| Phospholipase | 5.5 | 133 | 10 | 1 | 5 | 5 | 68.3 | M |
| Triose-phosphate isom. | 2.0 | 240 | 10 | 0 | 15 | 10 | 37.8 | Q |
| Glutathione Transferase | 6.0 | 230 | 15 | 0 | 20 | 10 | 39.5 | T |

\*Ammonium sulfate concentration at which 50% of the protein will precipitate. A concentration that is 0.5 M below and above this concentration will precipitate 25% and 75% of the protein, respectively. A concentration that is 1.0M below or 1.0M above will precipitate 0% and 100% of the protein, respectively